AI Article Synopsis
- - Antimicrobial peptides (AMPs) have various functions beyond their role in fighting infections, including potential antidiabetic effects, particularly those derived from amphibians like frogs.
- - The review highlights that certain AMPs can stimulate insulin release and identifies a significant peptide family consisting of nine antidiabetic peptides, emphasizing that an increase in positive charge and a decrease in hydrophobicity can enhance their insulinotropic effects.
- - The study suggests that amphibian-derived AMPs could be promising candidates for developing new treatments for type 2 diabetes, though it also notes the need for strategies to improve their stability and minimize side effects.
Article Abstract
Antimicrobial peptides, as an important member of the innate immune system, have various biological activities in addition to antimicrobial activity. There are some AMPs with antidiabetic activity, especially those isolated from amphibians. These peptides can induce insulin release via different mechanisms based on peptide type. In this review study, we collected all reported AMPs with antidiabetic activity. We also analyze the sequence and structure of these peptides for evaluation of sequence and structure effect on their antidiabetic activity. Based on this review, the biggest peptide family with antidiabetic activity is with nine antidiabetic peptides. Frogs are the most abundant source of antidiabetic peptides. Bioinformatics analysis showed that an increase of positive net charge and a decrease of hydrophobicity can improve the insulinotropic effect of peptides. Peptides with higher positive net charge and Boman index showed higher activity. Based on this review article, AMPs with antidiabetic activity, especially those isolated from amphibians, can be used as novel antidiabetic drug for type 2 diabetes disease. So, amphibians are potential sources for active peptides which merit further evaluation as novel insulin secretagogues. However, strategy for the increase of stability and positive activity as well as the decrease of negative side effects must be considered.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263238 | PMC |
| http://dx.doi.org/10.1155/2021/2894722 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants.
Diabetes Ther
December 2024
Novo Nordisk A/S, Vandtårnsvej 108-110, 2860, Søborg, Denmark.
Introduction: The glucagon-like peptide-1 (GLP-1) analogue semaglutide is approved as an oral formulation for the treatment of type 2 diabetes. This study aimed to confirm bioequivalence between a new, second-generation (2G) oral semaglutide formulation (1.5, 4 and 9 mg) and the initially approved first-generation (1G) formulation (3, 7 and 14 mg).
View Article and Find Full Text PDFAMPK-mTOR pathway modulates glycolysis reprogramming in unexplained recurrent spontaneous abortion.
BMC Pregnancy Childbirth
December 2024
Department of Obstetrics and Gynecology, The First Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou, Fujian, 350005, P.R. China.
Background: Recurrent spontaneous abortion (RSA), whose underlying cause has yet to be fully elucidated, is often classified as unexplained recurrent spontaneous abortion (URSA). Promoting the differentiation of CD4 T cells into Tregs may be the key to prevent URSA. The differentiation of CD4 T cells was controlled by mTOR, but the regulatory mechanism is still unclear.
View Article and Find Full Text PDFCell-Based Assays to Detect Innate Immune Response Modulating Impurities: Application to Biosimilar Insulin.
AAPS J
December 2024
Laboratory of Immunology, Office of Pharmaceutical Quality Research Division-IV, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Characterizing and mitigating factors that impact product immunogenicity can aid in risk assessment and/or managing risk following manufacturing changes. For follow-on products that have the same indication, patient population, and active product ingredient, the residual immunogenicity risk resides predominantly on differences in product and process related impurities. Characterizing differences in innate immune modulating impurities (IIRMI), which could act as adjuvants by activating local antigen presenting cells (APCs), can inform the immunogenicity risk assessment potentially reducing the need for clinical trials.
View Article and Find Full Text PDFBeta-cell, but not autonomic nervous system, function is related to MAFLD in early stages of glucose intolerance.
BMJ Open Diabetes Res Care
December 2024
Department of Endocrinology, Medical University-Sofia, Sofia, Bulgaria.
Introduction: Previous studies have suggested an association between beta-cell and autonomic function and metabolic-associated fatty liver disease (MAFLD). We explored the association between controlled attenuated parameter (CAP) and insulin secretion and action, as well as sympathetic and parasympathetic activity in normal (NGT) and impaired (IGT) glucose tolerance.
Research Design And Methods: Twenty-five NGT (age 44.
Investigating the antidiabetic properties of Apium graveolens extract and its inhibition of enzymes associated with hyperglycemia.
Int J Biol Macromol
December 2024
Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah 21955, Saudi Arabia. Electronic address:
Background: Apium graveolens Linn., also known as celery, is a member of the Apiaceae family and has shown promising pharmacological properties, including diabetes. Indeed, the current investigation aimed to investigate the potential inhibitory effects of A.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!